Plain-English translation of NCT07214727 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer's Disease research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new treatment called that is delivered directly into the spinal fluid through an injection. Researchers want to understand if this medication is safe, how well people tolerate it, and how the body handles it. The trial includes people with early Alzheimer's disease or mild cognitive impairment.
Currently, there are limited treatment options for early Alzheimer's disease. This medication is being tested because it may work differently than existing treatments by targeting the disease directly through the spinal fluid, which is close to the brain.
You likely qualify if…
You likely don't qualify if…
Some participants will receive spinal injections of the medication while others will receive placebo (inactive injections) during the first part of the study — neither you nor the doctors will know which you're getting. After that phase, all remaining participants will receive the actual medication. You will have regular visits for safety checks, blood tests, and to assess how you're doing, along with spinal procedures to deliver the injections.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
Canada
Netherlands